Increased TARC levels have been associated with improved survival in metastatic melanoma, attributed to the role of this cytokine in recruiting T cells to the tumor sites (10, 11), our study suggests this is also true for mRCC treated with ICI. The gene discussed is CCL17; the disease is metastatic melanoma.